309 related articles for article (PubMed ID: 24767842)
21. Discovery of indazoles as inhibitors of Tpl2 kinase.
Hu Y; Cole D; Denny RA; Anderson DR; Ipek M; Ni Y; Wang X; Thaisrivongs S; Chamberlain T; Hall JP; Liu J; Luong M; Lin LL; Telliez JB; Gopalsamy A
Bioorg Med Chem Lett; 2011 Aug; 21(16):4758-61. PubMed ID: 21742493
[TBL] [Abstract][Full Text] [Related]
22. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
23. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
[TBL] [Abstract][Full Text] [Related]
24. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
26. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
[TBL] [Abstract][Full Text] [Related]
27. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain.
Shirahashi H; Toriihara E; Suenaga Y; Yoshida H; Akaogi K; Endou Y; Wakabayashi M; Takashima M
Bioorg Med Chem Lett; 2019 Aug; 29(16):2320-2326. PubMed ID: 31235262
[TBL] [Abstract][Full Text] [Related]
28. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
30. Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
McBride CM; Renhowe PA; Heise C; Jansen JM; Lapointe G; Ma S; PiƱeda R; Vora J; Wiesmann M; Shafer CM
Bioorg Med Chem Lett; 2006 Jul; 16(13):3595-9. PubMed ID: 16603352
[TBL] [Abstract][Full Text] [Related]
31. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
32. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
[TBL] [Abstract][Full Text] [Related]
33. Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
Fuchi N; Iura Y; Kaneko H; Nitta A; Suyama K; Ueda H; Yamaguchi S; Nishimura K; Fujii S; Sekiya Y; Yamada M; Takahashi T
Bioorg Med Chem Lett; 2012 Jul; 22(13):4358-61. PubMed ID: 22633690
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
35. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
[TBL] [Abstract][Full Text] [Related]
37. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.
Gong L; Han X; Silva T; Tan YC; Goyal B; Tivitmahaisoon P; Trejo A; Palmer W; Hogg H; Jahagir A; Alam M; Wagner P; Stein K; Filonova L; Loe B; Makra F; Rotstein D; Rapatova L; Dunn J; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Hermann J; Kuglstatter A; Goldstein D
Bioorg Med Chem Lett; 2013 Jun; 23(12):3565-9. PubMed ID: 23664880
[TBL] [Abstract][Full Text] [Related]
38. Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.
Sheppeck JE; Gilmore JL; Xiao HY; Dhar TG; Nirschl D; Doweyko AM; Sack JS; Corbett MJ; Malley MF; Gougoutas JZ; Mckay L; Cunningham MD; Habte SF; Dodd JH; Nadler SG; Somerville JE; Barrish JC
Bioorg Med Chem Lett; 2013 Oct; 23(19):5442-7. PubMed ID: 23953070
[TBL] [Abstract][Full Text] [Related]
39. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
40. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]